Related Experiment Video

Updated: May 19, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment

Feng-Ming Hsu1, Shichuan Zhang, Benjamin P C Chen

  • 1Department of Oncology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.

Translational Cancer Research
|September 4, 2012
PubMed

Insights

DNA-dependent protein kinase catalytic subunit (DNA-PKcs) plays a role in DNA repair and cancer progression. Inhibiting DNA-PKcs shows promise in cancer therapy, but patient selection remains a challenge.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is crucial for DNA double-strand break repair via the non-homologous end-joining (NHEJ) pathway.
  • DNA-PKcs is implicated in maintaining genomic integrity, immune function, and signaling pathways like EGFR.
  • Elevated DNA-PKcs expression and activity are linked to cancer progression and treatment outcomes.

Purpose of the Study:

  • To review the association between DNA-PKcs and cancer development.
  • To discuss current strategies and mechanisms for inhibiting DNA-PKcs.
  • To highlight future challenges in understanding DNA-PKcs's role in cancer susceptibility and patient stratification.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of the role of DNA-PKcs in DNA repair and cancer.
  • Examination of anti-DNA-PKcs therapeutic strategies.

Main Results:

  • DNA-PKcs inhibition is a potential strategy to enhance radiotherapy and combined therapies.
  • Preclinical studies support the use of DNA-PKcs inhibitors in cancer treatment.
  • The precise correlation between DNA-PKcs activity and cancer susceptibility requires further investigation.

Conclusions:

  • DNA-PKcs is a significant target in oncology due to its role in DNA repair and cancer progression.
  • Inhibiting DNA-PKcs offers a promising avenue for sensitizing tumors to conventional treatments.
  • Future research should focus on identifying patient populations that will benefit most from DNA-PKcs inhibition.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...